| 1 | gamma delta t cells | | | | | | | 3 | 1.48% |
| 2 | publications investors press releases | | | | | | | 2 | 0.99% |
| 3 | board of directors scientific | | | | | | | 2 | 0.99% |
| 4 | investor contacts careers join | | | | | | | 2 | 0.99% |
| 5 | email alerts investor contacts | | | | | | | 2 | 0.99% |
| 6 | request email alerts investor | | | | | | | 2 | 0.99% |
| 7 | 8 2024 adicet bio | | | | | | | 2 | 0.99% |
| 8 | science gamma delta t | | | | | | | 2 | 0.99% |
| 9 | information investor resources investor | | | | | | | 2 | 0.99% |
| 10 | delta t cells autoimmune | | | | | | | 2 | 0.99% |
| 11 | financial information investor resources | | | | | | | 2 | 0.99% |
| 12 | t cells autoimmune cancer | | | | | | | 2 | 0.99% |
| 13 | governance highlights leadership and | | | | | | | 2 | 0.99% |
| 14 | governance governance highlights leadership | | | | | | | 2 | 0.99% |
| 15 | platform pipeline pipeline expanded | | | | | | | 2 | 0.99% |
| 16 | pipeline pipeline expanded access | | | | | | | 2 | 0.99% |
| 17 | pipeline expanded access policy | | | | | | | 2 | 0.99% |
| 18 | information stock quotechart historical | | | | | | | 2 | 0.99% |
| 19 | leadership board of directors | | | | | | | 2 | 0.99% |
| 20 | alerts investor contacts careers | | | | | | | 2 | 0.99% |
| 21 | terms of use privacy | | | | | | | 2 | 0.99% |
| 22 | about leadership board of | | | | | | | 2 | 0.99% |
| 23 | autoimmune cancer proprietary cell | | | | | | | 1 | 0.49% |
| 24 | and publications investors press | | | | | | | 1 | 0.49% |
| 25 | rule 5635c4 june 24 | | | | | | | 1 | 0.49% |
| 26 | presentations and publications investors | | | | | | | 1 | 0.49% |
| 27 | access policy presentations and | | | | | | | 1 | 0.49% |
| 28 | expanded access policy presentations | | | | | | | 1 | 0.49% |
| 29 | 5635c4 june 24 2024 | | | | | | | 1 | 0.49% |
| 30 | june 24 2024 adicet | | | | | | | 1 | 0.49% |
| 31 | adicet’s mission is | | | | | | | 1 | 0.49% |
| 32 | 2024 adicet bio announces | | | | | | | 1 | 0.49% |
| 33 | adicet bio announces fda | | | | | | | 1 | 0.49% |
| 34 | cell platform pipeline pipeline | | | | | | | 1 | 0.49% |
| 35 | proprietary cell platform pipeline | | | | | | | 1 | 0.49% |
| 36 | clearance of ind application | | | | | | | 1 | 0.49% |
| 37 | cells autoimmune cancer proprietary | | | | | | | 1 | 0.49% |
| 38 | news about leadership board | | | | | | | 1 | 0.49% |
| 39 | of ind application for | | | | | | | 1 | 0.49% |
| 40 | ind application for adi270 | | | | | | | 1 | 0.49% |